Murthy P Krishna
Damien Foundation India Trust, Chennai 600031.
J Indian Med Assoc. 2004 Dec;102(12):672-3, 683.
Every year around 4,00,000 new cases of leprosy occur in India and India contributes about 80% of the global leprosy case load. The prevalence of leprosy (case load per 1,00,000 population) has come down from 52 per 10,000 in 1981 to 2.4 per 10,000 in July 2004. There is no primary prevention for leprosy. Multidrug therapy is the only intervention available against the disease. As of July 2004 there were about 2,40,000 leprosy cases on record in India. There are thirteen states and union territories in India which have already eliminated leprosy. About 70% of the cases detected in India are paucibacillary which are less or non-infectious. Ever since the start of National Leprosy Eradication Programme in 1983, the number of new cases detected every year has not shown significant change. Leprosy cases are treated for 6 months or 12 months depending on whether they are PB or MB. The treatment completion rates are now found to be 85% for MB and 90% for PB. Phased introduction of MDT services has contributed to a large extent the static level of new case detection. Without complete coverage of MDT, it is difficult to achieve stable level of new case detection. Diagnostic efficiency of the staff is very important external factor influencing case detection rate. The most important factor that could have significant impact or prevalence is the coverage of the entire population with adequate MDT service.
印度每年约有40万例新的麻风病病例,全球约80%的麻风病病例来自印度。麻风病的患病率(每10万人中的病例数)已从1981年的万分之52降至2004年7月的万分之2.4。麻风病无法进行一级预防。联合化疗是对抗该疾病的唯一可用干预措施。截至2004年7月,印度有记录的麻风病病例约为24万例。印度有13个邦和中央直辖区已消除了麻风病。在印度检测出的病例中,约70%为少菌型,传染性较低或无传染性。自1983年国家麻风病根除计划启动以来,每年新发现的病例数没有显著变化。麻风病病例根据是少菌型还是多菌型接受6个月或12个月的治疗。目前发现,多菌型病例的治疗完成率为85%,少菌型病例为90%。分阶段引入联合化疗服务在很大程度上导致了新病例发现数量的停滞不前。如果联合化疗没有完全覆盖,就很难实现新病例发现数量的稳定。工作人员的诊断效率是影响病例发现率的非常重要的外部因素。可能对患病率产生重大影响的最重要因素是为全体人口提供充足的联合化疗服务。